Allogeneic Cell Therapy Global Market Analysis, Trends, Growth, Research And Forecast 2033

The new report published by The Business Research Company, titled "Allogeneic Cell Therapy Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the allogenic cell therapy market size has grown rapidly in recent years. It will grow from $0.97 billion in 2023 to $1.08 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The allogenic cell therapy market size is expected to see rapid growth in the next few years. It will grow to $1.67 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15976&type=smp

Allogeneic Cell Therapy Revolutionizing The Treatment Of Chronic Illnesses
The increasing prevalence of chronic diseases is expected to drive the growth of the allogeneic cell therapy market. Chronic disease is a long-lasting condition that typically requires ongoing medical attention and can limit daily activities or quality of life. The prevalence of chronic disease is due to altered habits, inheritance, and exposure to chemicals, toxins, and pollutants in the air. Allogeneic cell therapy holds significant potential for treating a wide range of chronic diseases by utilizing healthy cells from a donor to repair, replace, or modulate the dysfunctional cells or tissues in the recipient. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based medicine library, the number of people aged 50 and above who suffer from one or more chronic illnesses is expected to increase by 99.5% by 2050, from 71.52 million in 2020 to 142.66 million. Therefore, the increased prevalence of chronic diseases drives the growth of the allogeneic cell therapy market.

Innovative Cell Processing Platforms Strengthen Market Position Of Allogeneic Cell Therapy Companies
Major companies operating in the allogeneic cell therapy market are focusing on developing innovative solutions, such as cell processing platforms, to strengthen their position in the market. Cell processing platforms are systems and technologies used to prepare and manipulate cells for therapeutic applications, encompassing isolation, purification, expansion, modification, and quality control to ensure cells are suitable for clinical use. For instance, in March 2024, Getinge, a Sweden-based healthcare company, partnered with CellRev, a UK-based biotechnology company, to launch Livit ACE, a platform for continuous cell processing (Adherent Cell Expansion). This innovative platform integrates advanced automation and bioprocessing technologies, significantly enhancing the efficiency and scalability of cell production. Its unique features include state-of-the-art cell isolation and purification systems that ensure high cell purity and viability, robust expansion capabilities to produce large quantities of therapeutic cells, sophisticated genetic modification tools for precise cell engineering, and rigorous quality control measures to guarantee the safety and efficacy of the cell products.

The allogeneic cell therapy market covered in this report is segmented -

1) By Type: Stem Cell Therapies, Non-Stem Cell Therapies
2) By Therapeutic Area: Hematological Disorders, Dermatological Disorders, Other Therapeutic Area
3) By End User: Hospitals, Specialty Clinics, Research Organizations

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=15976&type=discount

Major companies operating in the allogeneic cell therapy market are Novartis AG, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Bluebird Bio Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Fortress Biotech Inc., Sorrento Therapeutics Inc., Eureka Therapeutics Inc., Juno Therapeutics Inc., Adaptimmune Therapeutics plc, Cellectis SA, TrakCel Ltd., Promab Biotechnologies Inc., Ziopharm Oncology Inc., Allogene Therapeutics Inc., Century Therapeutics Inc., Autolus Therapeutics plc, Bellicum Pharmaceuticals Inc., Minerva Biotechnologies Corporation, Celyad SA, TILT Biotherapeutics Ltd., CRISPR Therapeutics AG

Contents of the report:
1. Executive Summary
2. Allogeneic Cell Therapy Market Report Structure
3. Allogeneic Cell Therapy Market Trends And Strategies
4. Allogeneic Cell Therapy Market - Macro Economic Scenario
5. Allogeneic Cell Therapy Market Size And Growth
…..
27. Allogeneic Cell Therapy Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/allogeneic-cell-therapy-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.